86 completed, 17 unknown, 12 recruiting, 7 terminated. 45 Not applicable, 27 Phase 3, 26 Phase 2, 12 Phase 1, 9 Phase 4.
Follow Vulvitis: new trials by email Literature Review of Vulvitis trials Research Report on Vulvitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrated Care Pathway for Hormonally Mediated Vestibulodynia: a Feasibility and Acceptability Pilot HerAccess integrated care pathway - Vestibulodynia, Vulvodynia | Not applicable | Not yet recruiting | HerAccess ApS | 35 | 2027-01-01 | 2026-11-02 |
| Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment Blue LED Photobiomodulation - Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis | Not applicable | Not yet recruiting | Patricia Lordelo | 150 | 2026-07-30 | 2026-07-13 |
| Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence OCF001 Intravaginal Gel, Placebo Gel - Candidiasis, Vulvovaginal | Phase 2 | Recruiting | Sano Chemicals Inc | 36 | 2026-06-04 | 2026-06-15 |
| Large Algorithm Setting and Validation Study Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP - Bacterial Infections, Bacterial Infections and Mycoses | Recruiting | Nanopath, Inc | 1000 | 2026-06-03 | 2026-07-20 | |
| Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis Bioithas WOMAN® - Vulvovaginal Candidiasis (VVC) | Not applicable | Recruiting | Bioithas SL | 60 | 2026-05-25 | 2026-05-22 |
| The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study Vaginal lactoferrin, Usual care - Bacterial Vaginosis, Candida Vaginal | Not applicable | Recruiting | Guy's and St Thomas' NHS Foundation Trust | 114 | 2026-04-16 | 2026-05-29 |
| An Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group pHyph - Vulvovaginal Candidiasis (VVC) | Not applicable | Active not recruiting | Gedea Biotech AB | 48 | 2026-03-03 | 2026-05-14 |
| Does a Virtual Program for Pelvic Pain Improve Pain and Sexual Outcomes in Individuals With Provoked Vestibulodynia? Virtual online pelvic health program - Vulvodynia (Chronic Vulvar Pain), Vulvar Vestibulitis | Not applicable | Recruiting | Queen's University | 250 | 2025-12-17 | 2026-02-12 |
| Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes Non-interventional study - Vulvovaginitis, Candidal, Vulvovaginal Candidiasis | Recruiting | GlaxoSmithKline | 100 | 2025-11-12 | 2026-09-23 | |
| Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial Vaginosis Multi-Gyn FemiTotal - Bacterial Vaginosis, Vaginal Candidiasis | Not applicable | Recruiting | Karo Pharma AB | 80 | 2025-10-22 | 2026-10-02 |
| Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） Oteseconazole (VT-1161) 150mg capsule - Vulvovaginal Candidiasis | Not yet recruiting | Beijing Tsinghua Chang Gung Hospital | 3000 | 2025-08-10 | 2025-07-01 | |
| Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis Boric acid, Placebo - Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital | Phase 3 | Completed | pH-D Feminine Health LLC | 333 | 2025-08-08 | 2026-10-23 |
| Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC) vaginal cooling device - Vulvovaginal Candidiasis (VVC), Yeast Vaginitis | Not applicable | Recruiting | Coologics, Inc | 55 | 2025-05-22 | 2026-01-30 |
| Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP - Bacterial Vaginosis, Candida Vaginitis | Completed | Hoffmann-La Roche | 738 | 2024-12-30 | 2026-10-16 | |
| Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis Probiotic, Placebo - Vulvovaginal Candidiasis | Not applicable | Recruiting | The Archer-Daniels-Midland Company | 126 | 2024-10-15 | 2024-11-07 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Point of Care Diagnosis of Vaginal Infections Xpert® Xpress MVP test, Usual Care - Vaginitis, Bacterial Vaginosis | Not applicable | Completed | Sharon L Hillier | 351 | 2024-06-16 | 2026-04-08 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers CanProFem-AK - Candidosis Vaginal | Phase 1 | Completed | Industrial Microbiology LLP | 20 | 2024-06-01 | 2024-08-02 |
| DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy No intervention - Vulvovaginal Candidiasis | Active not recruiting | University Hospital, Antwerp | 300 | 2024-05-22 | 2026-08-13 |
Showing 20 of 133. Sign in to see all of them.
Candidiasis, Vulvovaginal (107) · Vaginosis, Bacterial (25) · Vulvar Vestibulitis (20) · Vaginitis (16) · Vulvodynia (15) · Candidiasis (13) · Vulvovaginitis (12) · Trichomonas Vaginitis (7) · Mycoses (6) · Vulvar Diseases (6) · Vaginal Diseases (5) · Dyspareunia (4) · Genital Diseases, Female (4) · Torulopsis (4) · Pain (3)
Female Urogenital Diseases and Pregnancy Complications (133) · Genital Diseases (133) · Female Urogenital Diseases (132) · Urogenital Diseases (131) · Genital Diseases, Female (129) · Vulvar Diseases (127) · Bacterial Infections and Mycoses (109) · Infections (108) · Vaginal Diseases (108) · Mycoses (102) · Vulvovaginitis (101) · Vaginitis (97) · Candidiasis (95) · Bacterial Infections (24)
Fluconazole (21) · Clotrimazole (8) · ibrexafungerp (8) · VT-1161 (6) · Metronidazole (3) · Miconazole (3) · Acupuncture Therapy (2) · Clindamycin (2) · Lactulose (2) · Lidocaine (2) · Probiotics (2) · boric acid (2) · butoconazole (2) · terconazole (2) · 6-phospho-beta-galactosidase (1)
Scynexis, Inc. (8) · Gedea Biotech AB (5) · Bayer (3) · Mycovia Pharmaceuticals Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Peking University Shenzhen Hospital (3) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Karo Pharma AB (2) · Maastricht University Medical Center (2) · Matinas BioPharma Nanotechnologies, Inc. (2) · Medinova AG (2) · Padagis LLC (2) · Perfect Care Distribution (2) · ProFem GmbH (2) · Queen's University (2)
United States (46) · China (6) · Spain (6) · Sweden (6) · India (5) · Austria (4) · France (4) · Russia (4) · Turkey (Türkiye) (4) · Brazil (3) · Canada (3) · Germany (3) · Poland (3) · United Kingdom (3) · Belgium (2)
David Angulo, MD (3) · Shangrong Fan, M.D. (3) · Alena Jandourek, MD (2) · Caroline Pukall, PhD (2) · Jacob Bornstein, MD (2) · Judith M. Schlaeger, PhD (2) · Monika Cardell, MD, PhD (2) · Adrian Gaspar, MD (1) · Aino Fianu Jonasson, MD, PhD (1) · Aleeza Gerstein, PhD (1) · Armin Witt, MD (1) · Arthur Y Fan, MD(CHN),PhD (1)
PMID 36396498, PMID 36255448, PMID 38319878, PMID 40970688, PMID 15162347, PMID 16648432, PMID 17128343, PMID 19305326, PMID 20733439, PMID 25877666, PMID 25887336, PMID 26136488, PMID 27073145, PMID 27383445, PMID 29304768, PMID 29514034, PMID 29534874, PMID 29686883, PMID 29697768, PMID 29912913, PMID 30184181, PMID 30341023, PMID 30406341, PMID 31592976, PMID 32818963, PMID 32940765, PMID 34555149, PMID 35005777, PMID 35943448, PMID 36130137, PMID 36387991, PMID 36395084, PMID 37474354, PMID 37640455, PMID 38154893, PMID 39979898, PMID 41471856, PMID 41845293, PMID 42117698, PMID 42464124, PMID 9307528
2008 (1), 2009 (1), 2014 (1), 2017 (1), 2023 (1), R01DK049524 (1), R01HD040123 (1)